Yes, I have commented on this before, but it looks like insurance companies pushed back against the high price of Ibalizumab, forcing proof the patients met the criteria before approving to pay. Because wIth IZ, not only do you have the high drug cost, but IV, adds some additional cost. As misiu noted it is coded the same from physician, so they singled out IZ, very likely because of the high cost. If they go in with the average $35k per year, I suspect there will be little resistance from insurance companies.


https://www.bcbsm.com/content/dam/public/Prov...policy.pdf

https://www.bluecrossnc.com/sites/default/fil...ogarzo.pdf